<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246620/" ref="ordinalpos=2033&amp;ncbi_uid=6891249&amp;link_uid=PMC4246620" image-link="/pmc/articles/PMC4246620/figure/f2-ol-09-01-0235/" class="imagepopup">Figure 2.  From: The expression of Wnt-1 inducible <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> protein-2 in astrocytoma: Correlation between pathological grade and clinical outcome. </a></div><br /><div class="p4l_captionBody">WISP-2 in normal brain and various grades of astrocytic gliomas. (A) Negative WISP-2 expression in normal human brain tissue. (B and C) Weak WISP-2 in stage I and II astrocytomas, respectively, with delicate staining of cytoplasm. (D and E) Markedly increased WISP-2 in malignant stage III and IV astrocytomas, respectively, with positive staining of cytoplasm (magnification, Ã—400). WISP-2, Wnt-1 inducible signaling pathway protein-2.</div></div>